Skip to main content
AdvisorShares Psychedelics ETF—— (—)Compass Pathways—— (—)Definium Therapeutics—— (—)GH Research—— (—)Helus Pharma—— (—)MIRA Pharmaceuticals—— (—)Neuphoria Therapeutics—— (—)Eli Lilly—— (—)Johnson & Johnson—— (—)AbbVie—— (—)Otsuka Pharmaceutical—— (—)Numinus Wellness—— (—)Optimi Health—— (—)PharmAla Biotech—— (—)Enveric Biosciences—— (—)Incannex Healthcare—— (—)Aurora Cannabis—— (—)Cronos Group—— (—)SNDL—— (—)Bright Minds Biosciences—— (—)PharmaTher Holdings—— (—)IM Cannabis—— (—)MariMed—— (—)Vireo Growth—— (—)
Loading prices
Back to the NewsWire

Marketscreener

Published November 16, 2026

Helus Pharma's psychedelic depression drug succeeds in late-stage study | MarketScreener

Read the full story at Marketscreener

Nov 16 - Helus Pharma said on Monday its experimental psychedelic drug met the main goal of a late-stage trial in patients with major depressive.

Surfaced by 4 Google Alerts

  • Psychedelics
  • Magic mushrooms
  • Psychedelic biotech
  • Ketamine